---
title: "Oncology Institute - CW22 | 8-K: FY2026 Q1 Revenue: USD 147.44 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285611563.md"
datetime: "2026-05-07T20:24:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285611563.md)
  - [en](https://longbridge.com/en/news/285611563.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285611563.md)
---

# Oncology Institute - CW22 | 8-K: FY2026 Q1 Revenue: USD 147.44 M

Revenue: As of FY2026 Q1, the actual value is USD 147.44 M.

EPS: As of FY2026 Q1, the actual value is USD -0.02.

EBIT: As of FY2026 Q1, the actual value is USD -4.579 M.

### Financial Highlights for Q1 2026

#### Gross Profit

Gross profit reached $23.3 million, marking a 35.2% increase compared to the prior year .

#### Net Loss

The company reported a net loss of -$2.5 million, significantly improved from a net loss of -$19.6 million in the same period last year .

#### Adjusted EBITDA

Adjusted EBITDA was -$2.4 million, an improvement from -$5.1 million in the prior year .

#### Cash and Cash Equivalents

Cash and cash equivalents stood at $30.3 million as of March 31, 2026 .

#### Segment Revenue

-   **Patient Services Revenue**: $59,087 thousand for the three months ended March 31, 2026, compared to $53,068 thousand for the same period in 2025 .
-   **Specialty Pharmacy Revenue**: Increased to $87,541 thousand in Q1 2026 from $49,293 thousand in Q1 2025, reflecting a 78% increase year-over-year . This growth was driven by record Part D fills and improved attachment rates .
-   **Clinical Trials & Other Revenue**: $813 thousand in Q1 2026, down from $2,045 thousand in Q1 2025 .

#### Operational Metrics

-   **The Oncology Institute (TOI) Contract Expansion**: Expanded its contract, bringing total Medicare Advantage lives to 200,000 across 25 counties in Florida, effective July 1, 2026 .
-   **Medicare Spending Savings**: The company saved approximately $2 million in Medicare spending as part of the CMS Enhancing Oncology Model performance program in period 3 .
-   **Loss from Operations**: Improved to -$6,513 thousand in Q1 2026 from -$9,911 thousand in Q1 2025 .
-   **Affiliated and Network Clinics**: Increased to 155 in Q1 2026 from 81 in Q1 2025 .
-   **Number of Markets Served**: Decreased to 17 in Q1 2026 from 18 in Q1 2025 .
-   **Lives under Value-Based Contracts**: Remained stable at 2.0 million for both Q1 2026 and Q1 2025 .

#### Cash Flow

-   **Net Cash and Cash Equivalents Used in Operating Activities**: -$2,215 thousand for the three months ended March 31, 2026, an improvement from -$4,988 thousand in the same period of 2025 .
-   **Free Cash Flow**: -$2,369 thousand in Q1 2026, an improvement of 41.2% from -$4,026 thousand in Q1 2025 .

### Outlook for Fiscal Year 2026

The Oncology Institute (TOI) reaffirmed its fiscal year 2026 guidance for revenue at $630 to $650 million and gross profit at $97 to $107 million . Adjusted EBITDA guidance remains unchanged at $0 to $9 million, while Free Cash Flow guidance was updated to $5 to $15 million, an increase from the previous range of -$15 to $5 million . The company expects approximately $150 million in capitated revenue for 2026 and anticipates Q2 2026 Adjusted EBITDA to be between -$1 million and $1 million .

### Related Stocks

- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)
- [STLNW.US](https://longbridge.com/en/quote/STLNW.US.md)

## Related News & Research

- [Navient announces Form 8-K filing for Q2 2026 financial results](https://longbridge.com/en/news/295144488.md)
- [Illumina ajukan Form 3; Chief Legal Officer Julie Ann Coletti laporkan kepemilikan manfaat awal](https://longbridge.com/en/news/295576352.md)
- [Immunic files Form 3 for director Elena Ridloff, reporting no beneficial ownership](https://longbridge.com/en/news/295459919.md)
- [Addentax Group files Form 3 initial beneficial ownership statement for Seah Chia Yee](https://longbridge.com/en/news/295694427.md)
- [EAT: Strong Q4 and FY26 results with robust guidance for FY27, led by Chili's sustained growth](https://longbridge.com/en/news/295653205.md)